<i>In Vivo</i>Effects of Preservative-free and Preserve Ocular Surface Study

Korean Journal of Ophthalmology: KJO 29, 270 DOI: 10.3341/kjo.2015.29.4.270

Citation Report

#	Article	IF	CITATIONS
1	A Comparison of the Effects of Benzalkonium Chloride on Ocular Surfaces between C57BL/6 and BALB/c Mice. International Journal of Molecular Sciences, 2017, 18, 509.	4.1	29
2	Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment. International Journal of Molecular Sciences, 2017, 18, 1697.	4.1	13
3	N-hydroxymethylglycinate with EDTA is an efficient eye drop preservative with very low toxicity: an in vitro comparative study. Cutaneous and Ocular Toxicology, 2018, 37, 71-76.	1.3	6
4	Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients. Journal of Ophthalmology, 2018, 2018, 1-7.	1.3	31
5	Tear biomarkers in latanoprost and bimatoprost treated eyes. PLoS ONE, 2018, 13, e0201740.	2.5	12
6	Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. PLoS ONE, 2019, 14, e0218886.	2.5	12
7	High-Frequency Application of Cationic Agents Containing Lubricant Eye Drops Causes Cumulative Corneal Toxicity in an <i>Ex Vivo</i> Eye Irritation Test Model. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 725-731.	1.4	5
8	Effects of Benzalkonium Chloride and Preservative-Free Composition on the Corneal Epithelium Cells. Journal of Ocular Pharmacology and Therapeutics, 2020, 36, 672-678.	1.4	6
9	Shape Memory Tube Plug for Fine-control of Intraocular Pressure by Glaucoma Devices. ACS Biomaterials Science and Engineering, 2020, 6, 3784-3790.	5.2	6
10	Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. British Journal of Ophthalmology, 2020, 104, bjophthalmol-2019-315623.	3.9	11
11	Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma. Seminars in Ophthalmology, 2021, 36, 103-109.	1.6	2
12	Comparison of preserved bimatoprost 0.01% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II. European Journal of Ophthalmology, 2021, , 112067212110065.	1.3	1
13	Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost. Pharmaceuticals, 2021, 14, 501.	3.8	6
14	Ocular benzalkonium chloride exposure: problems and solutions. Eye, 2022, 36, 361-368.	2.1	74
15	Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. International Ophthalmology, 2021, 41, 3825-3835.	1.4	10
16	Benzalkonium Chloride-Preserved Anti-Glaucomatous Eye Drops and Their Effect on Human Conjunctival Goblet Cells in vitro. Biomedicine Hub, 2021, 6, 69-76.	1.2	12
17	Efficacy and safety of newly developed preservative-free latanoprost 0.005% eye drops versus preserved latanoprost 0.005% in open angle glaucoma and ocular hypertension: 12-week results of a randomized, multicenter, controlled phase III trial. International Journal of Ophthalmology, 2021, 14, 1539-1547.	1.1	4
18	Antiseptic Drugs and Disinfectants. Side Effects of Drugs Annual, 2016, , 211-216.	0.6	7

#	Article	IF	CITATIONS
19	Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS ONE, 2018, 13, e0191398.	2.5	16
20	The effect of the main active substances of antihypertensive eye drops on condition of the eyes of glaucoma patients. Pacific Medical Journal, 2020, , 5-10.	0.3	1
21	SCD1-Fatty Acid Desaturase Inhibitor MF-438 Alleviates Latent Inflammation Induced by Preservative-Free Prostaglandin Analog Eye Drops. Journal of Inflammation Research, 2022, Volume 15, 793-806.	3.5	4
22	A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications. Ophthalmology and Therapy, 2022, 11, 1681-1704.	2.3	4
23	Topical glaucoma medications – Clinical implications for the ocular surface. Ocular Surface, 2022, 26, 19-49.	4.4	17
24	Benzalkonium Chloride, Even at Low Concentrations, Deteriorates Intracellular Metabolic Capacity in Human Conjunctival Fibroblasts. Biomedicines, 2022, 10, 2315.	3.2	3
25	Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy. Current Opinion in Ophthalmology, 2023, 34, S1-S13.	2.9	2
26	Norepinephrine as an Enhancer Promoting Corneal Penetration of Riboflavin for Transepithelial Corneal Crosslinking. Translational Vision Science and Technology, 2023, 12, 21.	2.2	1
27	Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy. Frontiers in Toxicology, 0, 5, .	3.1	3
28	Challenging the "Topical Medications-First―Approach to Glaucoma: A Treatment Paradigm in Evolution. Ophthalmology and Therapy, 2023, 12, 2823-2839.	2.3	1
29	Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis. Clinical Ophthalmology, 0, Volume 17, 3477-3489.	1.8	0
30	Benzalkonium chloride greatly deteriorates the biological activities of human corneal stroma fibroblasts in a concentration-dependent manner. Graefe's Archive for Clinical and Experimental Ophthalmology, 0, , .	1.9	0
31	Cord blood-derived biologics lead to robust axonal regeneration in benzalkonium chloride-injured mouse corneas by modulating the Il-17 pathway and neuropeptide Y. Molecular Medicine, 2024, 30, .	4.4	0
32	A Preservative-Free Approach – Effects on Dry Eye Signs and Symptoms After Cataract Surgery. Clinical Ophthalmology, 0, Volume 18, 591-604.	1.8	0
33	Differential Effects of Benzalkonium Chloride on Human Trabecular Meshwork Cells Not Treated or Treated with Transforming Growth Factor-β2 or Dexamethasone. Journal of Ocular Pharmacology and Therapeutics, 2024, 40, 189-196.	1.4	0

CITATION REPORT